Natco Pharma Limited · NSE:NATCOPHARM
Natco Pharma — Investor Presentation (June 2015)
18 slides from Natco Pharma's investor presentation, June 2015
Slide 1: Natco Pharma Limited
Natco Pharma Limited [June 2015] Strictly Private and Confidential
Slide 2: Important Disclosure
Important Disclosure This presentation has been prepared by Natco Pharma Limited (the “Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation should not be construed as legal, tax, i
Slide 3: Natco Pharma at a Glance
Natco Pharma at a Glance Vertically integrated pharmaceutical company with focus on niche therapeutic areas and complex products in Finished Dosage Formulations (“FDF”) and Active Pharmaceutical Ingredients (“APIs”) Diversified business model with presence across segments including Domestic & In
Slide 4: Company Evolution
Company Evolution 1986: Inaugurated 2003: Launched Oncology division 2009: Inaugurated NATCO Organics Parentals with introduction of flagship brand 2014: Established Natco Pharma at Chennai, India, with facilities Manufacturing facility VEENAT (generic Imatinib Mesylate) Australia Pty for sales & di
Slide 5: Key Business Segments
Key Business Segments Formulations API Others International Domestic Portfolio of niche and complex Market leader in India’s generic Filed 31 DMFs in US with Operates one pharmacy product pipeline for US oncology space led by flagship over 15 DMFs under store in US brands like Geftinat, Erlo
Slide 6: Key Growth Pillars in Place Supported by a Strong Foundation
Key Growth Pillars in Place Supported by a Strong Foundation to Continue the Track Record of Value Creation Expanding US footprint through a Leading Position Expanding Robust Pillars differentiated in Domestic Presence in RoW of Growth product pipeline of Oncology Market Markets niche and complex pr
Slide 7: Expanding US Footprint Through a Differentiated Product Pipeline
Expanding US Footprint Through a Differentiated Product Pipeline of Niche and Complex Products Revenue (INRmn) Pipeline of niche and complex generics products in US 35 ANDAs filings including 14 Para IV filings under USFDA review 1,050 targeting a combined market of US$14.8bn 840 620 14 approv
Slide 8: Expanding US Footprint Through a Differentiated Product Pipeline (Cont'd)
Expanding US Footprint Through a Differentiated Product Pipeline of Niche and Complex Products (Cont’d) Overview of Key Filings Key Brand Molecule Indication Dosage Form Para IV/FTF Para III Market Opportunity (US$mn) Copaxone 20mg Glatiramer 20mg Multiple Sclerosis PFS 2,410 Copaxone 40mg Glatira
Slide 9: Leading Position in Domestic Oncology Segment
Leading Position in Domestic Oncology Segment Pioneer in domestic oncology segment and holds leading market Revenue (INRmn) share in their operated portfolio of product 1,946 Entered the segment with launch of Veenat (Imatinib generic version) 1,572 1,403 1,322 1,236 Progressively widened its
Slide 10: Leading Position In Domestic Oncology Segment (Cont'd)
Leading Position In Domestic Oncology Segment (Cont’d) Ovarian Cancer Glioma Natdox-LP Temonat (Temozolomide) Lymphoma Breast Cancer Bendit Fulvenat (Fulvestrant) (Bendamustine) Leukemia Xtane (Exemestane) Veenat (Imatinib) Letronet (Letrozole) Lung Cancer Geftinat (Geftinib) HCC/RCC/DTC Sorafenat (
Slide 11: Expanding Presence in Domestic Specialty Pharma Segment
Expanding Presence in Domestic Specialty Pharma Segment Domestic Specialty Pharma Sovaldi Opportunity Portfolio of products catering primarily First Company in India to launch generic Sovaldi for the treatment of to Gastroenterology, Orthopaedics and Hepatitis C Critical Care ─ Medicine used for
Slide 12: Expanding RoW Presence
Expanding RoW Presence RoW formulation growth to be driven by big-ticket launches in EU, scale up in Latin America and Sovaldi Launch Ready with big ticket launches in limited competition drugs Europe ─ gGleevec: (~US$1.5bn) Canada ─ gTreanda: (~US$150mn) Established in 2012 Received Drug Esta
Slide 13: De-risked Business Model through Partnership with Global Pharmaceutical Players
De-risked Business Model through Partnership with Global Pharmaceutical Players Mitigation Strategy Adopted and successfully implemented partnership strategy for international formulations product ─ Has product specific partnerships with global generic players at different stages of a potential Pa
Slide 14: Strong In-House API Development with Vertical Integration
Strong In-House API Development with Vertical Integration for Key Formulation Products Strategically important business – develops APIs for captive Revenue (INRmn) consumption of its FDF portfolio as well as third party sales 2,571 Portfolio of 31 USDMFs with over 15 DMFs under development 2,221
Slide 15: Strong Research & Development Capabilities
Strong Research & Development Capabilities Cutting edge R&D capabilities demonstrated by its complex and niche product filings in formulations and API segments 70,000 sq ft of state of the art research facility fully equipped with capabilities across 14 ANDAs Approved synthetic chemistry, biotec
Slide 16: Commitment to Manufacturing Excellence with a Culture of Quality and Compliance
Commitment to Manufacturing Excellence with a Culture of Quality and Compliance Formulations Manufacturing Facilities Kothur Facility Nagarjuna Sagar Facility Dehradun Unit 6 Facility Dehradun Unit 7 Facility Guwahati Facility Capability: Tabets, Capsules, Capability: Ampoules, Vials, Capabili
Slide 17: Experienced Management
Experienced Management Holds Masters degree in Pharmaceutical Administration from the Brooklyn College of Pharmacy, US Over 42 years of experience in the Pharmaceutical Industry Mr. V.C Nannapaneni Chairman and Director Holds B.A. in Quantitative Economics and B.A. In History from Tufts Univer
Slide 18: Demonstrated Track Record of Topline and Earnings Growth
Demonstrated Track Record of Topline and Earnings Growth Revenue (INRmn) EBITDA (INRmn) and EBITDA Margin (%) 20.5% 22.2% 22.4% 26.0% 25.4% 8,402 7,556 2,131 6,729 1,960 5,329 1,507 4,651 1,185 952 FY2011 FY2012 FY2013 FY2014 FY2015 FY2011 FY2012 FY2013 FY2014 FY2015 PAT (INRmn) and PAT Margin (%) R